We also showed that HLA-G2 has a significant therapeutic effect against arthritis model mice [9]

We also showed that HLA-G2 has a significant therapeutic effect against arthritis model mice [9]. with a nM range for their dissociation constants, but did not show affinities to HLA-G2. The disulfide-linker HLA-G1 dimer further exhibited significant avidity effects. On the other hand, 4H84 and MEM-G1, which can be used for the Western blotting of HLA-G isoforms, can bind to native HLA-G2, while MEM-G9 and G233 cannot. These results reveal that HLA-G2 has a partially intrinsically disordered structure. Furthermore, MEM-G1, but not 4H84, competes with the LILRB2 binding of HLA-G2. These results provide novel insight into the functional GSK-LSD1 dihydrochloride characterization of HLA-G isoforms and their detection systems. Keywords:immune checkpoint, HLA-G, antibody, ELISA == 1. Introduction == Human leucocyte antigen (HLA)-G is one of the nonclassical major histocompatibility complex-I (MHC-I) molecules, a group that includes HLA-E and HLA-F [1]. Unlike classical MHC-I molecules, HLA-G shows restricted tissues expression, such as in the placenta, and some regulatory T cells [2,3]. HLA-G is reportedly not involved in the antigen presentation for stimulating the immune system but binds inhibitory leukocyte immunoglobulin-like receptors (LILR) molecules to suppress immune activation [4]. In the placenta, HLA-G plays a redundant role in the protection of the fetus from maternal immune responses. Notably, the amounts of HLA-G inversely correlate with the severity of autoimmune diseases [5,6,7]. We also demonstrated that the administration of the HLA-G molecule improved the symptoms of the collagen induced arthritis model mice and the atopic dermatitis model mice [8,9,10]. Furthermore, certain tumor cells also express HLA-G on the surface to suppress immune activation and escape immune surveillance [11,12]. Recent studies have exhibited the importance of the interactions of immune checkpoint inhibitory receptors with cognate ligands, such as program cell death protein 1 (PD-1) and PD-1Ls, and cytotoxic cell lymphocyte antigen-4 (CTLA-4) and GSK-LSD1 dihydrochloride CD80/CD86 interactions for cancer therapy [13,14,15]. Therefore, HLA-G is a prominent drug candidate for autoimmune diseases, and HLA-Gs-LILR interactions are also one of the targets for cancer immune therapy. HLA-G comprises seven isoforms (HLA-G1 to G7), which harbor GSK-LSD1 dihydrochloride different combinations of 1 1, 2, and 3 GSK-LSD1 dihydrochloride domains of heavy chain and 2-microglobulin (2m) in extracellular regions, together with the transmembrane and cytoplasmic domain [16]. HLA-G1 is a well characterized molecule among HLA-Gs, and its ectodomain consists of 1-2-3 domains, 2m, and a peptide. HLA-G2 also has a membrane-anchoring form and contains only two domains, 1 and 3, with a heavy chain in the extracellular region. Our recent biochemical and electron microscopic studies revealed that the ectodomain of HLA-G2 forms a homodimer via non-covalent interactions and strongly binds to LILRB2 [9,17]. Furthermore, HLA-G2 is considered to play an important role in humans who cannot produce functional HLA-G1 due to an HLA-Gnull allele [18,19]. HoWangYin et al. demonstrated that the Fc-fusion version of HLA-G2 can prolong the survival of a mouse with skin allografts [20]. We also showed that HLA-G2 has a significant therapeutic effect against arthritis model mice [9]. HLA-G3 and HLA-G4 are predicted to be expressed in membrane-anchoring forms, and contain only single 1 domain and 12 domains, respectively. HLA-G5, G6, and G7 are soluble forms (non-membrane-anchoring forms) of HLA-G1, G2, and G4, respectively [21]. In addition, the HLA-G1 molecule forms the disulfide-linked HLA-G1 homodimer, which reportedly plays an important role in immune suppression [22,23]. The structural complexity of HLA-G still makes it difficult to precisely evaluate the GSK-LSD1 dihydrochloride amount and function of each isoform in vivo. In order to measure HLA-G molecules in the serum of autoimmune and cancer patients, enzyme linked immunosolvent assays (ELISAs) were developed using monoclonal antibodies against HLA-G [24]. MEM-G9 and G233 are widely used in HLA-G ELISA as a capture antibody [25]. MEM-G9 reportedly binds surface expressed HLA-G1 but not HLA-G2, G3, or G4 [26]. Furthermore, the other SPN HLA-G antibody, 4H84, binds denatured or 2m-free HLA-G.